ArticleTranslational lung cancer research2025
Outcomes and prognostic insights in primary tracheal cancer: a multicenter retrospective study.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary tracheal tumors are exceedingly rare, comprising less than 0.1% of all respiratory system cancers and only 0.02-0.04% of all malignancies. Their rarity and clinical heterogeneity present significant challenges for diagnosis and treatment. This study aimed to evaluate treatment outcomes, identify prognostic factors, and compare recent findings with historical data to assess changes in clinical practice. Methods: We conducted a retrospective analysis of 31 patients treated between 2017 and 2022 at Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw and Gliwice, Poland. Demographic, clinical, pathological, and treatment-related data were collected. Overall survival (OS) was estimated using the Kaplan-Meier method, and prognostic factors were assessed using Cox proportional hazards models. Results: The most common histological types were squamous cell carcinoma (SCC, 51.7%) and adenoid cystic carcinoma (ACC, 29.0%). Among patients treated with curative intent, 60% underwent surgery and 40% received radical radiotherapy. All ACC patients were surgically treated, while 83% of SCC patients received radiotherapy. Radical treatment resulted in significantly better 5-year OS (35.7%) compared to palliative care (0%, P=0.002). Female sex (5-year OS: 55.3% Conclusions: Female sex, good performance status, and absence of nodal metastases were favorable prognostic factors. Radical treatment significantly improved outcomes, emphasizing the importance of early diagnosis and multidisciplinary management. Further multicenter studies are needed to establish optimal treatment strategies for this rare malignancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.